Clinical efficacy and safety of nedaplatin combined with paclitaxel liposome in treatment of advanced esophageal cancer

Cancer Research and Clinic

Volumn 28, Issue 11, 2016, Pages 748-751

  Li, Ke ^a   Liu, Jieqiong ^a  

^a Changsha First Hospital   (China)

Author keywords

Esophageal neoplasms; Nedaplatin; Paclitaxel liposome; Safety

Indexed keywords

NEDAPLATIN; PACLITAXEL;

ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; ESOPHAGUS CANCER; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 85014221633     PISSN: 10069801     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1006-9801.2016.11.007     Document Type: Article

References (10)

1. Ji YY, Hong YG, Li JK, et al. Comparison of paclitaxel liposome and paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer [j]. Journal of Basic and Clinical Oncology, 2013, 26(4): 301-303. DOI:10.3969/j.issn.l673-5412.2013.04.009.
2. Huo DD, Wang ZZ, Shi J, et al. Nedaplatin combined with docetaxel plus 5-fluorouracil in treatment of advanced esophageal carcinoma [j]. Chinese Journal of Practical Medicine, 2012, 39 (13): 82-83. DOI:10.3760/cma.j.issn.1674-4756.2012.13.039.
3. Yang XN, Wu YL. RECIST-New guidelines to evaluate the response to treatment in solid tumorsfj]. Journal of Evidence-Based Medicine, 2004, 4(2): 85-90, lll. DOI:10.3969/j.issn.l671-5144.2004.02.012.
4. Miao Y, Tian JR, Zhang WL, et al. Nedaplatin and paclitaxel in neoadjuvant chemotherapy for esophageal cancer and effect on immune function [j]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2015, 24 (36): 4053-4055. DOI: 10.3969/j.issn. 1008-8849.2015.36.024.
5. Mei L. Paclitaxel combined with cisplatin in the treatment of 25 cases of advanced esophageal cancer [j]. Cancer Research and Clinic, 2007, 19(10): 706-708. DOI:10.3760/cma.j.issn.1006-9801.2007.10.021.
6. Yue F, Jia T. Clinical observation of paclitaxel liposome and paclitaxel in the treatment of patients with advanced esophageal cancer [j]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2010, 18 (10): 1474-1475. DOI:10.3969/j.issn.l008-5971.2010.10.057.
7. Li JY, Ren XL, Bai X, et al. Paclitaxel and nedaplatin combined with chemotherapy in treatment of advanced esophageal cancer [j], Chinese Journal of Clinical Research, 2014, 27 (9): 1072-1073. DOI:10.13429/j.cnki.cjcr.2014.09.013.
8. Nakajima Y, Suzuki T, Haruki S, et al. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer [j], Hepatogastroenterology, 2008, 55(86- 87): 1631-1635.
9. Li QY, Huang LM, Ji XH, et al. Clinical efficacy of paclitaxel liposome plus nadaplatin in treatment of patients with advanced esophageal carcinoma [j]. Chinese Journal of Clinical Oncology and Rehabilitatien, 2015, 22 (11): 1339-1341. DOI:10.13455/j.cnki.cjcor.2015.11.17.
10. Cui HL, Liu HY, Yang J, et al. Clinical study of paclitaxel liposomes and paclitaxel in the treatment of advanced esophageal cancer [j], Chongqing Medicine, 2015, 44 (19): 2641-2643. DOI:10.3969/j.issn.1671-8348.2015.19.017.